Janus kinase inhibitors (JAKi) for the treatment of atopic dermatitis: real-life data on efficacy and safety in light of the Pharmacovigilance Risk Assessment Committee (PRAC) recommended measures.

Journal of the European Academy of Dermatology and Venereology : JEADV(2023)

Cited 0|Views8
No score
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined